High-dose meropenem — Competitive Intelligence Brief

High-dose meropenem (High-dose meropenem) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbapenem antibiotic. Area: Infectious Disease.

marketed Carbapenem antibiotic Penicillin-binding proteins (PBPs) Infectious Disease Small molecule

Target snapshot

High-dose meropenem (High-dose meropenem) — National University of Singapore. High-dose meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High-dose meropenem TARGET	High-dose meropenem	National University of Singapore	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
Maintaining carbapenem therapy	Maintaining carbapenem therapy	Assistance Publique - Hôpitaux de Paris	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases
Imipenem, Cilastatin and Relebactam	Imipenem, Cilastatin and Relebactam	Joseph L. Kuti, PharmD	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase inhibition
Meropenem Infusion	Meropenem Infusion	Unity Health Toronto	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
Meropenem Injection	Meropenem Injection	Institute of Liver and Biliary Sciences, India	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
MEROPENEM 2 grams TID	MEROPENEM 2 grams TID	BioVersys SAS	phase 3	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbapenem antibiotic class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Bayer · 1 drug in this class
3. BioVersys SAS · 1 drug in this class
4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
5. Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
6. Institute of Liver and Biliary Sciences, India · 1 drug in this class
7. National University of Singapore · 1 drug in this class
8. Unity Health Toronto · 1 drug in this class